Michael Cherny
Stock Analyst at Leerink Partners
(4.00)
# 516
Out of 4,944 analysts
113
Total ratings
54.12%
Success rate
10.45%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $148.12 | +25.57% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $23.06 | +21.42% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.17 | +156.41% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $663.17 | +20.63% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $21.56 | +6.68% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $468.00 | -29.49% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $48.33 | -17.24% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $65.90 | +13.81% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $64.02 | +40.58% | 2 | Feb 7, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $145.74 | +92.12% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $179.04 | -2.82% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $68.99 | +21.76% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $190.23 | +30.37% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $176.29 | +44.65% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.85 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $291.04 | -5.51% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.89 | +85.03% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $272.54 | -4.60% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $24.53 | -8.26% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $3.56 | +124.72% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.17 | +70.10% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.44 | +128.49% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $6.03 | +770.65% | 2 | Jan 5, 2022 |
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $148.12
Upside: +25.57%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $23.06
Upside: +21.42%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.17
Upside: +156.41%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $663.17
Upside: +20.63%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $21.56
Upside: +6.68%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $468.00
Upside: -29.49%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $48.33
Upside: -17.24%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $65.90
Upside: +13.81%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $64.02
Upside: +40.58%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $145.74
Upside: +92.12%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $179.04
Upside: -2.82%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $68.99
Upside: +21.76%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $190.23
Upside: +30.37%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $176.29
Upside: +44.65%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $13.85
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $291.04
Upside: -5.51%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.89
Upside: +85.03%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $272.54
Upside: -4.60%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $24.53
Upside: -8.26%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $3.56
Upside: +124.72%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.17
Upside: +70.10%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.44
Upside: +128.49%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $6.03
Upside: +770.65%